AChE-IN-29, a 3-OH pyrrolidine derivative, acts as a cholinesterase (ChE) inhibitor with potent activity against human acetylcholinesterase (hAChE), electric eel acetylcholinesterase (eeAChE), and equine butyrylcholinesterase (eqBChE), exhibiting IC50 values of 0.25 μM, 0.23 μM, and 0.72 μM, respectively. It is utilized in Alzheimer's disease research [1].

AChE-IN-29 (VA10) effectively inhibits AChE, BChE, and Aβ1-42 aggregation, demonstrating cholinesterase inhibitory activity against hAChE, eeAChE, and eqBChE with IC50 values of 0.25 μM, 0.23 μM, and 0.72 μM, respectively [1]. It also exhibits significant antioxidant activity with an IC50 of 24.12 μM in the DPPH assay [1]. Furthermore, AChE-IN-29 at concentrations of 5 μM, 10 μM, and 20 μM can inhibit both self-induced and hAChE-induced Aβ1-42 aggregation [1].

AChE-IN-29 (VA10) administered orally at doses of 2.5, 5, and 10 mg/kg improved memory and cognitive dysfunctions by inhibiting AChE activity [1]. At a 10 mg/kg oral dose, AChE-IN-29 restored cellular density in the hippocampal region [1].